PATHOGENESIS OF HELICOBACTER HEPATICUS

肝螺杆菌的发病机制

• 批准号: 7217249
• 负责人: CATHERINE S BECKWITH
• 金额: $ 0.38万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2003
• 资助国家: 美国
• 起止时间: 2003-02-01 至 2007-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7217249
• 关键词: American; Animal Model; Animals; Antibodies; Arts; Bacteria; Bacterial Infections; Bile fluid; Biological Assay; Biopsy; Campylobacter; Chronic; Chronic Active Hepatitis; Chronic Cholangitis; Chronic Disease; Clinical; Clinical Skills; Crohn' s disease; DNA; DNA Sequence; Depth; Development; Diagnostic; Disease; Doctor of Philosophy; Doctor of Veterinary Medicine; Educational process of instructing; Educational workshop; Ensure; Enteral; Environment; Essential Genes; Funding; Gastrointestinal tract structure; Gene Expression; Genome; Goals; Helicobacter; Helicobacter Infections; Helicobacter hepaticus; Helicobacter pylori; Hepatitis; Hepatobiliary; Human; Immune response; Infection; Inflammation; Inflammatory Bowel Diseases; Integration Host Factors; International; Intestinal Diseases; Intestines; Journals; Knock-out; Laboratories; Laboratory Animal Medicine; Laboratory mice; Libraries; Link; Liver; Liver and Intrahepatic Biliary Tract Carcinoma; Liver diseases; Malignant Neoplasms; Medicine; Mentors; Missouri; Modeling; Molecular; Molecular Genetics; Mouse Strains; Mus; Neoplasms; Organism; Outcome; Pathogenesis; Pathologist; Pathology; Patients; Persons; Prevention strategy; Primary biliary cirrhosis; Process; Publications; Range; Reagent; Reporting; Research; Research Personnel; Research Project Grants; Resources; Rodent; Sampling; Serum; Stomach; Techniques; Time; Training; Transgenic Organisms; Ulcerative Colitis; Universities; Virulence; Virulence Factors; college; comparative; human disease; novel; pathogen; primary sclerosing cholangitis; tool; tumor

DESCRIPTION (Provided by applicant): Catherine Beckwith, D.V.M, Ph.D., Diplomate, American College of Laboratory Animal Medicine, received her doctoral training with Dr. Lela Riley at the University of Missouri where her research focused on development of diagnostic assays, identification of virulence factors, and characterization of the pathogenesis of rodent Helicobacter infections. With the SERCA, Dr. Beckwith will build upon her background in research and obtain additional training that will allow her to develop into an independently funded research investigator. Dr. Beckwith will train in the rich intellectual environment of SU where Dr. Stanley Falkow, an internationally renowned leader in bacterial pathogenesis research, will mentor her. Dr. Beckwith is co-sponsored by Linda Cork, D.V.M., Ph.D., a veterinary pathologist and the Department Chair of Comparative Medicine, who will ensure that she has the resources and time to carry out her research. Clinical and teaching responsibilities will be only as sufficient to maintain her clinical skills. Dr. Beckwith will conduct an in-depth research project, present her research at national scientific meetings, participate in laboratory meetings, attend specialized courses at Cold Spring Harbor Laboratory, and attend seminars and journal clubs related to bacterial pathogenesis. Dr. Beckwith's research will use a molecular and genetic approach to identify and characterize virulence factors in H. hepaticus, the cause of IBD, chronic active hepatitis, and hepatocellular tumors in mice. The H. hepaticus-infected mouse is an animal model of chronic bacterial infection, which closely mimics human hepatobiliary and inflammatory bowel diseases. Dr. Beckwith will create a transposon library in H. hepaticus and identify virulence factors through negative selection in mice. Novel virulence factors and the host response will be characterized using traditional and cutting edge techniques including global gene expression analysis with microarrays. Characterization of virulence factors is essential to understanding the pathogenesis of IBD and hepatitis caused byH. hepaticus. Recent evidence suggests a link between helicobacters and chronic hepatobiliary diseases in humans. The long-term goal of the proposal is to develop new strategies for prevention and treatment of chronic liver and intestinal disease in humans.

描述（由申请人提供）：Catherine Beckwith，D.V.M，Ph.D.，美国实验动物医学院专科医生，在密苏里州大学接受Lela Riley博士的博士培训，她的研究重点是诊断测定的开发、毒力因子的鉴定和啮齿动物螺杆菌感染发病机制的表征。 Beckwith博士将利用她的研究背景，获得额外的培训，使她能够发展成为一名独立资助的研究调查员。 Beckwith博士将在SU丰富的知识环境中接受培训，国际知名的细菌致病机理研究领导者Stanley Falkow博士将指导她。Beckwith博士由琳达科克，D.V.M.，哲学博士、兽医病理学家和比较医学系主任，谁将确保她有资源和时间来开展她的研究。 临床和教学职责将只足以保持她的临床技能。 Beckwith博士将进行深入的研究项目，在国家科学会议上展示她的研究，参加实验室会议，参加冷泉港实验室的专业课程，并参加与细菌发病机制有关的研讨会和期刊俱乐部。 博士贝克威斯的研究将使用分子和遗传方法来识别和表征H.在小鼠中的IBD、慢性活动性肝炎和肝细胞肿瘤的原因。 螺杆肝感染小鼠是慢性细菌感染的动物模型，其非常类似于人类肝胆和炎症性肠病。 贝克维斯博士将在H.并通过小鼠阴性选择鉴定毒力因子。 新的毒力因子和宿主反应将采用传统的和尖端的技术，包括全球基因表达分析与微阵列。 毒力因子的特性对于理解IBD和H.肝 最近的证据表明，螺旋杆菌和人类慢性肝胆疾病之间的联系。 该提案的长期目标是制定预防和治疗人类慢性肝脏和肠道疾病的新策略。